In male CF-1 mice after controlled cortical impact, an extended MDL-28170 regimen reduced the calpain-specific spectrin fragment SBDP145 at 24 h by 40% in hippocampus and 44% in cortex; abbreviated treatment did not. A separate histological experiment using the extended regimen found no reduction in neurodegeneration at 48 h. Thus, biochemical protection did not establish reduced tissue damage in this model. [2]
Short-duration intravenous MDL-28170 failed to significantly preserve retrograde axonal transport four days after optic nerve stretch in male rats. The authors could not establish sufficient target engagement in optic nerve axons and reported transient bradycardia and respiratory difficulty during the initial bolus in approximately 15–20% of rats. These findings limit generalization across neural injury models. [3]
In mouse oxygen-induced retinopathy, daily intraperitoneal MDL 28170 at 0.25 mg/kg improved vascular coverage and reduced retinal hypoxic area versus vehicle. Doses of 0.5 mg/kg and higher inhibited neovascular regrowth, indicating a model-specific dose window rather than a uniform pro-vascular effect. [1]
Regimen-dependent reduction of post-traumatic spectrin breakdown
Animal study · Young adult male CF-1 mice, controlled cortical impact; ipsilateral cortex and hippocampus [2]
The four-dose regimen reduced calpain-specific SBDP145 at 24 h, whereas the two-dose regimen failed to reduce it. Sham and injured vehicle groups were included; biochemical protection did not establish overall tissue protection.
Conditions shared by the study groups
- Route
- IV then IP
- Vehicle
- Polyethylene glycol 300:ethanol, 9:1
- Extended four-dose regimen
- Model: Young adult male CF-1 mice, controlled cortical impact; ipsilateral cortex and hippocampus
- Frequency: Four administrations
- Treatment course: 15 min to 4 h 45 min after injury
- Abbreviated two-dose regimen
- Model: Young adult male CF-1 mice, controlled cortical impact; ipsilateral cortex and hippocampus
- Frequency: Two administrations
- Treatment course: First 45 min after injury
Methods and source locations
Compound reported in the paper: MDL-28170; Compound label in the paper: MDL 28170
Evidence concerns the named research compound in the reported model; no salt conversion, stereochemical equivalence beyond the paper, or validation of an Adooq lot is asserted.
Methods: MDL-28170 preparation, Tissue processing and immunoblotting, Statistical analysis; Results: Effect of MDL-28170 administration on calpain-mediated cytoskeletal degradation; Fig. 2A–C and caption
Calpain-specific 145-kDa alpha-spectrin breakdown product in ipsilateral hippocampus and cortex at 24 h: Western immunoblotting of SBDP145; n=8 mice/group; displayed mean ± standard error; p<0.05 versus vehicle by Student–Newman–Keuls after ANOVA. — Methods: MDL-28170 preparation, Tissue processing and immunoblotting, Statistical analysis; Results: Effect of MDL-28170 administration on calpain-mediated cytoskeletal degradation; Fig. 2A–C and caption
SBDP145 after abbreviated two-dose treatment at 24 h: 20 mg/kg IV at 15 min plus 40 mg/kg IP at 45 min; n=8 mice/group; Fig. 2A. — Methods: MDL-28170 preparation, Tissue processing and immunoblotting, Statistical analysis; Results: Effect of MDL-28170 administration on calpain-mediated cytoskeletal degradation; Fig. 2A–C and caption
Extended four-dose regimen · Methods: MDL-28170 preparation, Tissue processing and immunoblotting, Statistical analysis; Results: Effect of MDL-28170 administration on calpain-mediated cytoskeletal degradation; Fig. 2A–C and caption
Abbreviated two-dose regimen · Methods: MDL-28170 preparation, Tissue processing and immunoblotting, Statistical analysis; Results: Effect of MDL-28170 administration on calpain-mediated cytoskeletal degradation; Fig. 2A–C and caption
No reduction of histological neurodegeneration at 48 h
Animal study · Young adult male CF-1 mice with controlled cortical impact [2]
The extended regimen that reduced spectrin breakdown in the separate 24-h experiment did not reduce total histological neurodegeneration at 48 h. The endpoint combined silver-stained tissue and contusion cavity volume.
Conditions shared by the study groups
- Route
- IV then IP
- Frequency
- Four administrations
- Treatment course
- 15 min to 4 h 45 min after injury
- Vehicle
- Polyethylene glycol 300:ethanol, 9:1
- Extended regimen, histological endpoint
- Model: Male CF-1 mice, controlled cortical impact
Methods and source locations
Compound reported in the paper: MDL-28170; Compound label in the paper: MDL 28170
Evidence concerns the named research compound in the reported model; no salt conversion, stereochemical equivalence beyond the paper, or validation of an Adooq lot is asserted.
Methods: Silver staining, MDL-28170 preparation, Statistical analysis; Results: Effect of MDL-28170 on post-traumatic neurodegeneration; Fig. 4 and caption
Silver-stained tissue plus cortical contusion lesion, normalized to contralateral hemisphere volume, at 48 h: de Olmos aminocupric silver staining; blinded image analysis; injured vehicle and MDL groups n=8 each; sham n=6. Four sham animals were historical controls. — Methods: Silver staining, MDL-28170 preparation, Statistical analysis; Results: Effect of MDL-28170 on post-traumatic neurodegeneration; Fig. 4 and caption
Extended regimen, histological endpoint · Methods: Silver staining, MDL-28170 preparation, Statistical analysis; Results: Effect of MDL-28170 on post-traumatic neurodegeneration; Fig. 4 and caption
Short-duration treatment failed to preserve axonal transport
Animal study · Adult male Long–Evans rats (300–400 g), unilateral optic nerve stretch [3]
Short-duration intravenous MDL-28170 did not significantly preserve retrograde Fluorogold transport at four days. Contralateral uninjured eyes served as within-animal controls. This negative result is specific to this isolated axonal-injury model and regimen.
Conditions shared by the study groups
- Route
- Intravenous
- Frequency
- One bolus then continuous infusion
- Treatment course
- Bolus over 10–15 min; infusion initiated immediately after bolus and continued 2.5 h; injury 30 min after bolus completion
- Vehicle
- DMSO
- Short-duration IV pretreatment
- Model: Adult male Long–Evans rat optic nerve stretch
- Reported limits: Target engagement in optic nerve axons uncertain; transient cardiorespiratory adverse observations reported.
Methods and source locations
Compound reported in the paper: MDL-28170; Compound label in the paper: MDL 28170
Evidence concerns the named research compound in the reported model; no salt conversion, stereochemical equivalence beyond the paper, or validation of an Adooq lot is asserted.
Methods: Rat optic nerve stretch, MDL-28170 therapy, Assessment of FG axonal transport in RGCs, Statistical analysis; Results: FG-cells in the retina; Fig. 2 and caption; Discussion: Limitations
Decrease in Fluorogold-labeled retinal ganglion cells, injured versus contralateral uninjured retina, at four days: Fluorogold retrograde transport with TUJ1 immunostaining and blinded counting; vehicle n=5 animals, MDL n=7; preplanned injured-group comparison p=0.93. — Methods: Rat optic nerve stretch, MDL-28170 therapy, Assessment of FG axonal transport in RGCs, Statistical analysis; Results: FG-cells in the retina; Fig. 2 and caption; Discussion: Limitations
Short-duration IV pretreatment · Methods: Rat optic nerve stretch, MDL-28170 therapy, Assessment of FG axonal transport in RGCs, Statistical analysis; Results: FG-cells in the retina; Fig. 2 and caption; Discussion: Limitations
Moderate dosing improved retinal revascularization; higher doses inhibited regrowth
Animal study · C57BL/6 mouse pups, oxygen-induced ischemic retinopathy [1]
Daily MDL 28170 at 0.25 mg/kg improved retinal vascular coverage and reduced hypoxic area versus vehicle. Doses of 0.5 mg/kg and higher inhibited neovascular regrowth, establishing a non-monotonic response in this model.
Conditions shared by the study groups
- Route
- Intraperitoneal
- Frequency
- Once daily
- Vehicle
- Not specified in retrieved main text
- Moderate-dose MDL 28170
- Model: C57BL/6 mouse pups, oxygen-induced retinopathy
- Treatment course: P12–P16 for P17 endpoint; P12–P20 for P21 endpoint
- Reported limits: Pup sex and vehicle composition not specified.
- Higher-dose limitation
- Model: C57BL/6 mouse pups, oxygen-induced retinopathy
- Treatment course: P12–P16; retinal vascular coverage assessed at P17
- Reported limits: No exact effect size extracted from dose curve.
Methods and source locations
Compound reported in the paper: MDL-28170; Compound label in the paper: MDL 28170
Evidence concerns the named research compound in the reported model; no salt conversion, stereochemical equivalence beyond the paper, or validation of an Adooq lot is asserted.
Methods 2.1–2.2,2.6; Results 3.2; Fig. 2A–D and caption
Avascular retinal area at P17: Whole-mount TRITC-lectin imaging; Fig. 2B: p<0.05, n≥11 animals/group; Fig. 2A,C show inhibitory response at higher doses. — Methods 2.1–2.2,2.6; Results 3.2; Fig. 2A–D and caption
Hypoxic retinal area at P17 and P21: Hypoxyprobe staining; Fig. 2D: p<0.01, n≥9 animals/group; no exact percent reduction digitized. — Methods 2.1–2.2,2.6; Results 3.2; Fig. 2A–D and caption
Moderate-dose MDL 28170 · Methods 2.1–2.2,2.6; Results 3.2; Fig. 2A–D and caption
Higher-dose limitation · Methods 2.1–2.2,2.6; Results 3.2; Fig. 2A–D and caption